347 results about "Prostate cancer" patented technology

The invention provides a prostate cancer multi-modal data federal learning method and system, and relates to the technical field of intelligent medical treatment and distributed artificial intelligence cross, and the method comprises the steps: selecting a plurality of key feature regions in a feature space as a reference basis based on updated global feature parameters, and constructing a feature distribution topological structure; performing partition division on the feature distribution topological structure to generate a plurality of feature subspaces; calculating a spatial characteristic index according to the characteristic density and the distribution characteristic of each characteristic subspace, and generating a weight adjustment coefficient based on the spatial characteristic index; and dynamically optimizing the updated global feature parameters by using the weight adjustment coefficient to obtain optimized federal learning model parameters. Through multi-modal data feature alignment, gradient compression transmission, global gradient aggregation and parameter dynamic optimization, a complete prostate cancer multi-modal data federated learning framework is constructed, and model performance and cross-mechanism cooperation efficiency are improved.

The invention belongs to the technical field of medical image processing, and particularly relates to a multimodal prostate cancer detection method fusing a memory mechanism and a space Transform, which comprises the following steps: constructing a multimodal prostate cancer detection network, and realizing prostate cancer detection through the multimodal prostate cancer detection network; according to the method, a Triad structured path is designed, efficient cooperation and guide fusion of multi-modal information is realized through division cooperation of dominant, auxiliary and control modalities, an encoder adopts a Swinin-Unet architecture, a window attention mechanism is combined, local details are kept, and meanwhile, the global modeling capability is enhanced; a dynamic memory unit DMU is further introduced, historical features are fused, a space gating mechanism is introduced, and the consistency and continuity of semantic expression are enhanced; in the decoding stage, an MESTrans module is embedded, and semantic alignment and boundary enhancement between modals are realized under multiple scales.

The present invention relates to a hetero (aromatic) ring-substituted cyclic diamine compound, the preparation thereof and the use thereof in the preparation of a drug for treating and / or preventing tumors. The structural formula of the compound is as shown in (I). The compound has a significant inhibitory effect on the growth of cells of tumors such as leukemia, lymphoma, breast cancer, melanoma, ovarian cancer, colorectal cancer, cervical cancer, lung cancer, prostate cancer, esophageal cancer, glioma, kidney cancer, nasopharyngeal carcinoma, liver cancer, gastric cancer and pancreatic cancer. Compared with the prior art, the compound of the present invention has a broad-spectrum anti-tumor activity, has a good effect on inhibiting tumors, and has an effect of degrading PD-L1 proteins, and is thus a PD-L1 immunomodulator.

A biomimetic nano immunosubstrate material, a preparation method therefor and a use thereof. The biomimetic nano immunosubstrate material comprises a PDMS@AgNPs@ZIF-67 biomimetic immunosubstrate and a gold nanorod immunoprobe. The preparation method comprises the following steps: (S10) preparing a ZIF-67 nanomaterial; (S20) preparing a PDMS@AgNPs@ZIF-67 biomimetic polymeric material; (S30) preparing a PDMS@AgNPs@ZIF-67 biomimetic immunosubstrate material; and (S40) synthesizing a gold nanorod immunoprobe. A SERS substrate having both a synergistic enhancement effect and a molecular anchoring capability is constructed on a MOFs-modified biomimetic substrate, thereby improving the efficiency and sensitivity of prostate cancer tests.

The present invention relates to methods of treating prostate cancer in a subject in need thereof, comprising administering a therapeutically effective amount of a KLK2xCD3 bispecific antibody or bispecific binding fragment thereof to the subject to treat the prostate cancer.

The invention discloses an ROS-responsive prostate cancer targeting prodrug as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The prodrug is formed by covalently linking a prostate cancer targeting peptide SYEELR, a ROS (reactive oxygen species) response type ketal thiol (TK) connexon and an active molecule Devimistat. The preparation method comprises the following two steps: firstly, coupling Devimistat with a TK linker to obtain an intermediate Dev-TK, and then coupling the intermediate Dev-TK with an SYEELR peptide fragment to obtain a target product. The prodrug can specifically break and release Devimistat in a tumor high active oxygen microenvironment, and active targeting delivery is realized by virtue of the SYEELR peptide. The invention provides a novel prostatic cancer treatment strategy with accurate targeting, controllable release, enhanced curative effect and toxicity reduction potential.

The present provides a method of treating ovarian cancer, breast cancer, gastrointestinal cancer, lung cancer, cancer of the brain or prostate cancer in a subject in need thereof, comprising administering to the subject a first amount of a selective PARP1 inhibitor or a pharmaceutically acceptable salt thereof, and a second amount of an ATR inhibitor or a pharmaceutically acceptable salt thereof. Also disclosed are compositions and kits comprising a PARP inhibitor and ATR inhibitor.

The present disclosure provides a high-energy, low toxicity radiopharmaceutical composition comprising actinium that performs as an anti-tumor agent for targeted radionuclide therapy and has improved shelf-life stability. Specifically, the radiopharmaceutical composition may include 225Ac-PSMA I&T, sodium ascorbate, and optionally hydrochloric acid. The radiopharmaceutical composition may be suitable for administration to a patient in need thereof, such as for the purpose of treating prostate cancer.

The invention provides an organoid chip for screening micro-ecological drugs as well as application and a preparation method of the organoid chip, and relates to the technical field of biological medicines. The invention provides a chip integrating intestinal epithelium, a prostate cancer organ and a bladder cancer organ, which is used for researching how microecological preparations, such as probiotics, metabolites and the like, affect tumor microenvironment and immunotherapy effects. The chip can simulate interaction of intestinal tract-tumor axis, and provides an in-vitro evaluation system for precise tumor immunotherapy.

The invention relates to a hetero (aromatic) ring substituted cyclic diamine compound, preparation thereof and application of the hetero (aromatic) ring substituted cyclic diamine compound in preparation of drugs for treating and / or preventing tumors. The structural formula of the compound is shown as (I). The compound has an obvious growth inhibition effect on tumor cells of leukemia, lymphoma, breast cancer, melanoma, ovarian cancer, colorectal cancer, cervical cancer, lung cancer, prostate cancer, esophagus cancer, glioma, kidney cancer, nasopharynx cancer, liver cancer, stomach cancer, pancreatic cancer and the like. The compound disclosed by the invention has broad-spectrum anti-tumor activity; the compound has a good tumor inhibition effect and a PD-L1 protein degradation effect, and is a PD-L1 immunomodulator.

This invention relates to talazoparib, or a pharmaceutically acceptable salt thereof, in combination with enzalutamide, or a pharmaceutically acceptable salt thereof, for the treatment of homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer and methods of increasing overall survival thereof.

The invention relates to a model privacy processing method based on model pruning and a prostate cancer early warning method. The method comprises the following steps: acquiring a sample data set; performing first training on the initial first network model through the sample data set to obtain the first network model after the first training and importance parameters of each neuron in the first network model; the initial first network model is trained for the second time through the sample data set, the first network model after the second time of training is obtained, and the loss functions of the first time of training and the second time of training are different; performing model pruning processing based on the importance parameters of each neuron, the first network model after the first training and the first network model after the second training to obtain a second network model; configuring homomorphic encryption parameters based on the public key; and based on the homomorphic encryption parameter, performing privacy processing on the model component of the second network model to obtain a target network model. According to the scheme of the embodiment, model processing efficiency and safety can be considered.

The invention described herein provides biological markers for the diagnosis, prognosis, and monitoring of prostate cancer.

The invention belongs to the field of medicines, and particularly relates to a nanosheet capable of activating an STING pathway and improving microwave ablation as well as a preparation method and application of the nanosheet. The nanosheet is prepared from MXenes through organic acid treatment, organic alkali dispersion, STING agonist compounding and phospholipid modification, and has good microwave thermal conversion efficiency and an STING pathway activation function. The combined microwave ablation can enhance the immunogenic death of tumor cells, promote the maturation of dendritic cells, doubly activate immune response and effectively inhibit the growth and metastasis of prostatic cancer, provides a new strategy for the treatment of prostatic cancer, and can be used for preparing drugs for treating prostatic cancer.

The application discloses application of a naphthalene nitrile derivative in preparation of an antitumor pharmaceutical composition, in particular, application of a 2-(imino)-naphthalene nitrile derivative in preparation of an antitumor pharmaceutical composition. The 2-(imino)-naphthalene nitrile derivative provided by the application has a significant inhibiting effect on colon cancer, liver cancer, lung cancer, prostate cancer, cervical cancer, neuroglioma and breast cancer, exhibits excellent antitumor characteristics, can be used as a leading drug molecule for resisting tumors, and has a good development and application prospect in development of antitumor drugs.

The present disclosure relates to methods of treating PTEN-deficient metastatic hormone- sensitive prostate cancer (mHSPC) in patients in need thereof, the methods comprising administering to the patients a combination comprising capivasertib or a pharmaceutically acceptable salt thereof; and abiraterone or an ester prodrug thereof, or a pharmaceutically acceptable salt thereof.

The present invention provides methods for the detection of aggressive prostate cancer, and methods for detecting aggressive prostate cancer based on comparisons to a mixed control population of subjects with non-aggressive prostate cancer or not having prostate cancer.

Provided herein are methods of identifying a subject with prostate cancer (such as a human or veterinary subject) who will respond to enzalutamide therapy. In particular examples, the methods can determine with high accuracy whether a subject is likely to respond to enzalutamide therapy. Also provided are methods for treating a subject who is likely to respond to enzalutamide, for example by administering enzalutamide to the subject.

Provided herein are kits and methods useful for cancer diagnosis, prognosis, research, and therapy. In particular, provided herein are methods for diagnosis, prognosis and / or treatment of prostate cancer based on expression levels of cancer markers.

This document provides bifunctional compounds, one part of which (e.g., lenalidomide, thalidomide) is a binder of an E3 ubiquitin ligase (e.g., Cereblon) and the other part of which is a binder of a target protein (e.g., a kinase (e.g., CDK (e.g., CDK9 and / or CDK12))) to induce the degradation of the target protein CDK9 and / or CDK12. Pharmaceutical compositions comprising bifunctional compounds are also provided, as well as methods for treating and / or preventing diseases (e.g., proliferative diseases such as cancers (e.g., ovarian cancer, breast cancer, or prostate cancer)). Methods for inducing the degradation of target proteins (e.g., kinases (e.g., CDK (e.g., CDK9 and / or CDK12))) and methods for inducing apoptosis in biological samples or subjects by administering the bifunctional compounds or compositions described herein are also provided.

This invention discloses an ERβ-targeted hydrogen peroxide-responsive near-infrared fluorescent probe, its preparation method, and its applications, belonging to the field of medical technology. The fluorescent probes of this invention are dicyanomethylene-4H-benzodihydropyran compounds P1 and P2 containing borate ester groups, with the following structural formula. These fluorescent probes use DCM-OH as a backbone, acting as both a fluorophore and an ERβ ligand. The borate ester group is the H2O2 responsive group. The introduction of the borate ester group disrupts the push-pull effect of the DCM-OH fluorophore, preventing fluorescence emission. However, in a high-concentration H2O2 environment, the borate ester group is specifically cleaved by H2O2, subsequently exhibiting strong initiation fluorescence and enabling tumor imaging in vitro and in vivo. This invention brings new opportunities for the diagnosis and research of prostate cancer.

The invention provides a dalotamide monophosphate compound shown as a formula I or a pharmaceutically acceptable salt thereof, and n is an integer of 1-3, preferably an integer of 1-2. The compound provided by the invention can be used for preparing medicines for treating adult patients with non-metastatic castration-resistant prostate cancer with high metastasis risk.

The present application relates to nanoparticles for the targeted delivery of CRISPR / Cas13 systems, and their therapeutic use to treat diseases and disorders such as prostate cancer and COVID-19.

Disclosed are direct-binding dual hypoxia-inducible factor (HIF) inhibitors and their use for treating cancer, including, but not limited to, breast, colorectal, lung, melanoma, pancreatic, and prostate cancer as a monotherapy and in combination with anti-CTLA-4 or anti-PD-1 immunotherapies. The dual HIF inhibitors also can be used for treating diseases, disorders, or conditions associated with ocular neovascularization, including, but not limited to, diabetic macular edema, diabetic retinopathy, and other ischemic retinopathies (including, but not limited to retinal vein occlusion, sickle cell retinopathy, retinopathy of prematurity, Norrie's disease, and Coat's disease), corneal neovascularization, and the treatment or prevention of neurovascular (wet-type) age-related macular degeneration.

The present disclosure provides a high-energy, low toxicity radiopharmaceutical composition comprising actinium that performs as an anti-tumor agent for targeted radionuclide therapy and has improved shelf-life stability. Specifically, the radiopharmaceutical composition may include 225Ac-PSMA I&T, sodium ascorbate, and optionally hydrochloric acid. The radiopharmaceutical composition may be suitable for administration to a patient in need thereof, such as for the purpose of treating prostate cancer.

Provided are a jellyfish polypeptide, and a preparation method therefor and a use thereof. The jellyfish polypeptide provided by the present disclosure or a jellyfish polypeptide obtained by using the preparation method provided by the present disclosure exhibits a significant inhibitory effect on multiple tumors including colorectal cancer, lung cancer and prostate cancer, and also has a regulating function on mammalian immune systems.

This disclosure provides a method for detecting prostate cancer in human subjects, wherein a Cu-64 PSMA I&T composition of about 7 mCi to about 9 mCi is administered to the human subject, images are obtained 1 hour to 4 hours after administration, and wherein the obtained images maintain acceptable image quality for up to 4 hours after administration.

Provided are methods and compositions, for treating prostate cancer by administering to a patient in need thereof a therapeutically effective amount of a PARP inhibitor, e.g., niraparib; a therapeutically effective amount of a CYP17 inhibitor, e.g., abiraterone acetate, and a therapeutically effective amount of a glucocorticoid, e.g., prednisone.

This disclosure provides compounds of formula (I) or pharmaceutically acceptable salts thereof, methods for preparing the same, and their use in the treatment and / or diagnosis of cancers such as neuroblastoma, prostate cancer, pancreatic cancer, leukemia, osteosarcoma, hepatoblastoma, lung cancer, colon cancer, breast cancer, skin cancer, thyroid cancer, and / or rhabdoid cancer. JPEG2026522940000099.jpg50170

The application discloses a prostate cancer diagnosis model based on multi-parameter ultrasonic images and a training method thereof. The prostate cancer diagnosis model comprises a convolutional neural network for extracting image features, a feature reconstruction algorithm module, a long short-term memory neural network for extracting ultrasonic contrast semantic features, and a decision fusion classification network. The training method comprises establishing a training sample set, then inputting the training sample into the prostate cancer lesion diagnosis model for training until the error between the predicted value output by the prostate cancer lesion diagnosis model and the real value of the lesion target classification converges, and a qualified prostate cancer lesion diagnosis model is obtained. The application can extract the optimal features in different parameter ultrasonic images by virtue of the advantages of multiple feature extraction networks, and can obtain a prostate cancer diagnosis model capable of extracting rich features, recognizing accurate results and being robust by processing the time sequence features of ultrasonic contrast through the long short-term memory network.